Venus Remedies, 526953, VENUSREM Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

623.97
10.10
10

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

842.30
N/A
1.51

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

-0.61
-3.98
-2.85

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-7.61
-12.84
0.67

PAT CAGR (%)

10 Years
5 Years
3 Years

-
-
-31.19

P:E (Median)

8 Years
5 Years
3 Years

5.40
6.84
-

P:BV (Average)

8 Years
5 Years
3 Years

0.37
0.31
0.35

EV:EBITDA (Average)

8 Years
5 Years
3 Years

6.25
7.30
8.36

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 21 Mar 20 Var% Dec 20 Dec 19 Var% Sep 20 Sep 19 Var% Jun 20 Jun 19 Var%
Net Sales 102.44 79.22 29.31% 114.07 92.23 23.68% 118.41 80.08 47.86% 179.71 70.82 153.76%
Expenses 94.57 72.82 29.87% 101.03 80.27 25.86% 113.25 65.55 72.77% 158.91 60.66 161.97%
EBITDA 7.87 6.41 22.78% 13.04 11.96 9.03% 5.16 14.53 -64.49% 20.80 10.17 104.52%
EBIDTM 7.68% 8.09% 11.43% 12.97% 4.36% 18.15% 11.57% 14.36%
Other Income 3.36 2.70 24.44% 1.15 1.61 -28.57% 11.74 0.73 1,508.22% 1.51 0.42 259.52%
Interest 0.87 0.00 0 1.73 4.00 -56.75% 7.33 4.91 49.29% 2.79 6.01 -53.58%
Depreciation 9.18 6.22 47.59% 8.42 8.23 2.31% 8.35 8.34 0.12% 8.33 8.26 0.85%
PBT 21.74 -5.93 - 8.50 1.33 539.10% 8.82 2.02 336.63% 2.01 -3.69 -
Tax -16.91 0.82 - 2.21 0.99 123.23% 1.49 0.16 831.25% 0.00 0.00 0
PAT 38.65 -6.74 - 6.29 0.35 1,697.14% 7.33 1.86 294.09% 2.01 -3.69 -
PATM 37.73% -8.51% 5.52% 0.38% 6.19% 2.32% 1.12% -5.21%
EPS 28.84 -5.03 - 4.70 0.26 1,707.69% 5.47 1.39 293.53% 1.50 -2.75 -

Description Mar 21 Mar 20 Var% Dec 20 Dec 19 Var% Sep 20 Sep 19 Var% Jun 20 Jun 19 Var%
Net Sales 111.37 83.06 34.08% 121.94 96.86 25.89% 126.07 87.89 43.44% 188.75 73.65 156.28%
Expenses 106.88 75.53 41.51% 103.86 86.06 20.68% 115.42 75.19 53.50% 173.19 63.86 171.20%
EBITDA 4.50 7.53 -40.24% 18.08 10.79 67.56% 10.65 12.71 -16.21% 15.55 9.78 59.00%
EBIDTM 4.04% 9.07% 14.83% 11.14% 8.45% 14.46% 8.24% 13.28%
Other Income 3.49 1.37 154.74% 1.83 1.77 3.39% 12.28 1.35 809.63% 2.04 0.82 148.78%
Interest 0.96 -1.82 - 1.81 4.07 -55.53% 7.39 4.91 50.51% 2.85 6.18 -53.88%
Depreciation 9.38 6.47 44.98% 8.70 8.48 2.59% 8.61 8.56 0.58% 3.59 8.50 -57.76%
PBT 18.20 -4.56 - 13.86 0.02 69,200.00% 14.52 0.58 2,403.45% 1.97 -4.07 -
Tax -16.91 0.82 - 2.21 0.99 123.23% 1.49 0.16 831.25% 0.00 0.00 0
PAT 35.11 -5.38 - 11.65 -0.96 - 13.03 0.42 3,002.38% 1.97 -4.07 -
PATM 31.53% -6.48% 9.56% -0.99% 10.33% 0.47% 1.05% -5.53%
EPS 28.45 -4.36 - 9.44 -0.78 - 10.55 0.34 3,002.94% 1.60 -3.30 -

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Net Sales 514.63 322.36 301.84 355.07 375.45 402.69 451.88 526.06 461.34 405.19 356.68 Net Sales Growth 59.65% 6.80% -14.99% -5.43% -6.76% -10.89% -14.10% 14.03% 13.86% 13.60% Cost Of Goods Sold 336.69 176.81 181.78 205.42 186.69 194.64 213.05 298.96 263.27 226.04 199.89 Gross Profit 177.94 145.55 120.06 149.65 188.76 208.05 238.82 227.10 198.07 179.15 156.80 GP Margin 34.58% 45.15% 39.78% 42.15% 50.28% 51.67% 52.85% 43.17% 42.93% 44.21% 43.96% Total Expenditure 467.76 279.29 267.55 311.51 328.16 323.14 364.94 392.83 342.85 299.29 265.60 Power & Fuel Cost - 3.41 3.50 3.02 3.08 2.90 3.28 3.11 2.86 2.49 2.28 % Of Sales - 1.06% 1.16% 0.85% 0.82% 0.72% 0.73% 0.59% 0.62% 0.61% 0.64% Employee Cost - 33.79 30.26 27.82 25.02 25.02 27.26 25.57 23.24 20.58 17.30 % Of Sales - 10.48% 10.03% 7.84% 6.66% 6.21% 6.03% 4.86% 5.04% 5.08% 4.85% Manufacturing Exp. - 18.35 18.98 34.28 75.01 58.94 73.60 20.75 19.72 17.45 16.47 % Of Sales - 5.69% 6.29% 9.65% 19.98% 14.64% 16.29% 3.94% 4.27% 4.31% 4.62% General & Admin Exp. - 15.22 9.79 11.86 12.20 10.85 14.36 13.81 11.10 11.34 10.75 % Of Sales - 4.72% 3.24% 3.34% 3.25% 2.69% 3.18% 2.63% 2.41% 2.80% 3.01% Selling & Distn. Exp. - 31.72 23.24 29.11 26.17 30.78 33.39 30.64 22.66 21.18 18.92 % Of Sales - 9.84% 7.70% 8.20% 6.97% 7.64% 7.39% 5.82% 4.91% 5.23% 5.30% Miscellaneous Exp. - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.20 18.92 % Of Sales - 0% 0% 0% 0% 0% 0% 0% 0% 0.05% 0% EBITDA 46.87 43.07 34.29 43.56 47.29 79.55 86.94 133.23 118.49 105.90 91.08 EBITDA Margin 9.11% 13.36% 11.36% 12.27% 12.60% 19.75% 19.24% 25.33% 25.68% 26.14% 25.54% Other Income 17.76 3.58 4.51 1.19 3.10 0.67 0.55 0.41 0.39 0.38 0.29 Interest 12.72 13.05 25.15 35.44 35.87 36.74 40.70 29.29 24.45 27.26 18.71 Depreciation 34.28 31.05 32.95 32.73 39.32 40.47 44.74 38.61 31.76 23.86 17.91 PBT 41.07 2.55 -19.30 -23.42 -24.80 3.01 2.04 65.73 62.67 55.15 54.76 Tax -13.21 1.96 -1.15 3.16 -4.56 1.81 -2.51 4.78 5.53 5.12 7.28 Tax Rate -32.16% -31.31% 4.07% -13.49% 18.39% 60.13% -123.04% 7.27% 8.82% 9.28% 13.29% PAT 54.28 -8.23 -27.11 -26.58 -20.24 1.20 4.55 60.95 57.15 50.03 47.48 PAT before Minority Interest 54.28 -8.23 -27.11 -26.58 -20.24 1.20 4.55 60.95 57.15 50.03 47.48 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 10.55% -2.55% -8.98% -7.49% -5.39% 0.30% 1.01% 11.59% 12.39% 12.35% 13.31% PAT Growth 760.34% - - - - -73.63% -92.53% 6.65% 14.23% 5.37% EPS 40.51 -6.14 -20.23 -19.84 -15.10 0.90 3.40 45.49 42.65 37.34 35.43

Description TTM Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Net Sales 548.13 341.46 321.89 372.41 400.04 418.27 463.99 541.56 468.64 409.84 363.09 Net Sales Growth 60.53% 6.08% -13.57% -6.91% -4.36% -9.85% -14.32% 15.56% 14.35% 12.88% Cost Of Goods Sold 340.60 174.31 181.95 205.08 227.07 238.51 268.94 300.00 262.26 225.91 201.50 Gross Profit 207.53 167.15 139.94 167.33 172.97 179.77 195.05 241.55 206.38 183.92 161.59 GP Margin 37.86% 48.95% 43.47% 44.93% 43.24% 42.98% 42.04% 44.60% 44.04% 44.88% 44.50% Total Expenditure 499.35 300.64 289.37 332.94 349.32 337.11 374.81 403.33 348.53 306.96 273.00 Power & Fuel Cost - 4.73 4.86 4.29 4.14 4.01 3.80 3.38 3.05 2.71 2.72 % Of Sales - 1.39% 1.51% 1.15% 1.03% 0.96% 0.82% 0.62% 0.65% 0.66% 0.75% Employee Cost - 46.02 42.10 39.31 34.27 32.44 32.36 30.45 27.30 24.83 20.38 % Of Sales - 13.48% 13.08% 10.56% 8.57% 7.76% 6.97% 5.62% 5.83% 6.06% 5.61% Manufacturing Exp. - 20.84 21.01 36.10 42.48 15.70 17.29 22.10 20.61 18.18 17.05 % Of Sales - 6.10% 6.53% 9.69% 10.62% 3.75% 3.73% 4.08% 4.40% 4.44% 4.70% General & Admin Exp. - 17.57 11.85 13.52 13.26 11.97 15.67 14.74 11.82 12.14 11.54 % Of Sales - 5.15% 3.68% 3.63% 3.31% 2.86% 3.38% 2.72% 2.52% 2.96% 3.18% Selling & Distn. Exp. - 37.18 27.60 34.65 28.10 34.48 36.75 32.65 23.50 22.98 19.82 % Of Sales - 10.89% 8.57% 9.30% 7.02% 8.24% 7.92% 6.03% 5.01% 5.61% 5.46% Miscellaneous Exp. - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.20 19.82 % Of Sales - 0% 0% 0% 0% 0% 0% 0% 0% 0.05% 0% EBITDA 48.78 40.82 32.52 39.47 50.72 81.16 89.18 138.23 120.11 102.88 90.09 EBITDA Margin 8.90% 11.95% 10.10% 10.60% 12.68% 19.40% 19.22% 25.52% 25.63% 25.10% 24.81% Other Income 19.64 5.31 6.09 2.39 4.28 2.01 0.68 0.47 0.44 0.49 0.40 Interest 13.01 13.34 25.41 35.56 36.38 37.98 41.21 29.40 24.63 27.49 18.86 Depreciation 30.28 32.01 33.98 33.83 40.26 41.68 46.00 40.22 33.08 25.02 18.98 PBT 48.55 0.78 -20.77 -27.53 -21.64 3.51 2.65 69.08 62.84 50.85 52.63 Tax -13.21 1.96 -1.15 3.16 -4.56 1.81 -2.51 4.78 5.53 3.78 6.41 Tax Rate -27.21% -24.41% 3.87% -11.48% 21.07% 51.57% -94.72% 6.92% 8.80% 7.43% 12.18% PAT 61.76 -10.00 -28.57 -30.69 -17.08 1.70 5.16 64.30 57.31 47.08 46.22 PAT before Minority Interest 61.76 -10.00 -28.57 -30.69 -17.08 1.70 5.16 64.30 57.31 47.08 46.22 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 11.27% -2.93% -8.88% -8.24% -4.27% 0.41% 1.11% 11.87% 12.23% 11.49% 12.73% PAT Growth 718.22% - - - - -67.05% -91.98% 12.20% 21.73% 1.86% EPS 46.09 -7.46 -21.32 -22.90 -12.75 1.27 3.85 47.99 42.77 35.13 34.49

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Shareholder's Funds 332.25 340.95 367.99 394.23 444.43 466.24 467.42 392.24 319.11 246.59 Share Capital 12.34 12.34 12.34 12.34 11.44 11.44 11.44 10.54 9.74 9.13 Total Reserves 319.91 328.61 355.65 381.89 432.99 454.79 455.97 376.92 300.35 233.27 Non-Current Liabilities 96.03 136.75 157.89 179.52 212.03 221.50 161.27 147.18 113.50 99.41 Secured Loans 23.92 60.88 86.02 112.69 134.55 150.91 114.28 103.89 75.45 65.97 Unsecured Loans 48.34 55.20 50.84 49.13 56.47 51.34 25.22 25.22 23.68 22.02 Long Term Provisions 6.63 5.32 4.50 4.29 3.79 3.78 3.31 2.91 2.50 1.94 Current Liabilities 209.93 254.46 222.61 193.71 177.59 157.06 207.33 190.06 154.13 124.69 Trade Payables 33.96 33.41 27.19 30.56 23.90 25.76 28.14 17.87 12.33 6.11 Other Current Liabilities 93.94 107.61 76.87 45.70 36.63 13.99 54.12 57.88 43.22 40.27 Short Term Borrowings 81.42 108.92 117.23 115.70 115.09 115.40 110.08 95.68 83.24 63.17 Short Term Provisions 0.61 4.52 1.32 1.76 1.97 1.91 14.99 18.63 15.33 15.14 Total Liabilities 638.21 732.16 748.49 767.46 834.05 844.80 836.02 729.48 586.74 470.69 Net Block 271.47 346.89 369.93 389.38 433.52 425.77 416.09 380.92 335.86 274.04 Gross Block 589.77 674.06 669.01 655.78 660.61 612.50 555.61 481.83 405.01 319.32 Accumulated Depreciation 318.30 327.17 299.08 266.40 227.09 186.73 139.52 100.91 69.15 45.28 Non Current Assets 360.33 478.57 499.96 517.54 575.53 618.72 567.61 500.20 413.61 331.63 Capital Work in Progress 24.63 64.76 64.76 66.25 80.37 78.30 67.80 47.81 23.00 15.31 Non Current Investment 0.14 0.14 0.14 28.74 28.74 28.74 28.74 28.74 28.74 28.37 Long Term Loans & Adv. 64.08 66.78 65.13 33.17 32.90 85.91 54.98 42.74 26.01 13.91 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 277.89 253.59 248.53 249.93 258.53 226.08 268.41 229.28 173.13 139.07 Current Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 136.44 140.94 135.98 139.69 137.69 140.44 141.46 126.40 96.19 75.43 Sundry Debtors 29.78 31.39 44.15 41.91 53.88 59.37 62.80 53.11 44.33 36.41 Cash & Bank 1.44 1.28 3.64 3.15 3.04 3.52 4.38 6.26 2.91 2.91 Other Current Assets 110.23 5.15 4.84 0.00 63.91 22.76 59.77 43.51 29.70 24.31 Short Term Loans & Adv. 54.51 74.83 59.93 65.18 63.91 22.76 59.77 43.51 29.70 24.11 Net Current Assets 67.96 -0.87 25.93 56.22 80.94 69.02 61.08 39.21 19.00 14.38 Total Assets 638.22 732.16 748.49 767.47 834.06 844.80 836.02 729.48 586.74 470.70

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Shareholder's Funds 323.37 332.52 361.91 388.67 437.62 456.68 461.61 379.13 307.29 236.92 Share Capital 12.34 12.34 12.34 12.34 11.44 11.44 11.44 10.54 9.74 9.13 Total Reserves 311.03 320.18 349.57 376.33 426.18 445.24 450.17 363.81 288.53 223.59 Non-Current Liabilities 95.82 136.68 158.47 179.52 212.05 221.55 161.75 147.18 113.51 99.41 Secured Loans 24.19 61.29 86.60 112.69 134.57 150.95 114.76 103.89 75.45 65.97 Unsecured Loans 47.87 54.73 50.84 49.13 56.47 51.34 25.22 25.22 23.68 22.02 Long Term Provisions 6.63 5.32 4.50 4.29 3.79 3.78 3.31 2.91 2.50 1.94 Current Liabilities 218.53 263.62 230.38 196.81 193.14 162.83 210.99 191.25 153.22 124.53 Trade Payables 36.70 36.00 29.33 29.73 25.14 29.56 31.22 18.76 12.55 7.02 Other Current Liabilities 95.65 110.30 78.47 46.16 42.71 15.96 54.70 58.18 43.44 40.07 Short Term Borrowings 85.58 112.80 121.26 119.16 123.32 115.40 110.08 95.68 83.24 63.17 Short Term Provisions 0.61 4.52 1.32 1.76 1.97 1.91 14.99 18.63 13.99 14.27 Total Liabilities 637.72 732.82 750.76 765.00 842.81 841.06 834.35 717.56 574.02 460.86 Net Block 289.37 364.45 389.20 406.18 452.48 443.65 439.46 401.42 355.39 293.28 Gross Block 623.96 707.02 702.77 686.50 679.57 641.12 587.38 511.00 430.25 343.15 Accumulated Depreciation 334.59 342.57 313.57 280.32 227.09 197.47 147.93 109.58 74.87 49.86 Non Current Assets 349.77 467.39 490.50 505.60 565.75 607.85 562.24 491.97 404.40 322.49 Capital Work in Progress 24.63 64.76 64.76 66.25 80.37 78.30 67.80 47.81 23.00 15.31 Non Current Investment 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 35.77 38.18 36.53 33.17 32.90 85.91 54.98 42.74 26.01 13.91 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 287.95 265.43 260.27 259.41 277.07 233.21 272.11 225.58 169.63 138.37 Current Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 141.12 142.73 138.17 140.60 143.29 142.87 142.26 128.03 96.82 75.43 Sundry Debtors 30.69 38.04 47.27 47.29 61.59 63.22 64.99 47.11 40.10 35.74 Cash & Bank 2.13 2.81 3.98 3.56 7.07 3.62 4.41 6.36 2.95 3.12 Other Current Assets 114.01 5.15 4.84 0.00 65.12 23.51 60.47 44.08 29.77 24.07 Short Term Loans & Adv. 58.29 76.70 66.00 67.96 65.12 23.51 60.47 44.08 29.77 23.87 Net Current Assets 69.43 1.81 29.88 62.59 83.93 70.38 61.12 34.33 16.41 13.84 Total Assets 637.72 732.82 750.77 765.01 842.82 841.06 834.35 717.55 574.03 460.86

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Cash From Operating Activity 77.15 43.65 51.58 61.77 41.91 66.76 52.56 50.66 38.06 39.34 PBT 2.55 -19.30 -23.42 -24.80 3.01 2.04 65.73 62.67 55.15 54.76 Adjustment 40.39 59.20 64.73 69.30 53.72 81.90 35.95 39.38 27.76 23.16 Changes in Working Capital 19.78 3.75 10.27 17.27 -14.82 -17.18 -49.12 -51.39 -44.85 -38.58 Cash after chg. in Working capital 62.71 43.65 51.58 61.77 41.91 66.76 52.56 50.66 38.06 39.34 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 14.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -4.64 -11.27 -11.48 -18.06 3.20 -67.15 -93.75 -102.47 -93.63 -98.23 Net Fixed Assets 124.42 -5.05 -11.74 18.95 -50.18 -67.39 -93.77 -101.63 -93.38 -94.69 Net Investments 0.00 0.00 28.60 0.00 0.00 0.00 0.00 0.00 -0.37 -3.58 Others -129.06 -6.22 -28.34 -37.01 53.38 0.24 0.02 -0.84 0.12 0.04 Cash from Financing Activity -72.35 -34.74 -39.61 -43.60 -45.59 -0.47 39.31 55.15 55.57 59.80 Net Cash Inflow / Outflow 0.16 -2.36 0.49 0.11 -0.48 -0.86 -1.88 3.35 0.00 0.91 Opening Cash & Equivalents 1.28 3.64 3.15 3.04 3.52 4.38 6.26 2.91 2.91 2.00 Closing Cash & Equivalent 1.44 1.28 3.64 3.15 3.04 3.52 4.38 6.26 2.91 2.91

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Cash From Operating Activity 77.01 45.33 31.19 58.93 46.88 67.80 52.65 52.15 41.67 37.35 PBT 0.78 -20.77 -27.53 -21.64 3.51 2.65 69.08 62.84 50.85 52.63 Adjustment 41.56 60.72 66.24 70.61 56.41 83.56 37.21 40.72 29.96 24.74 Changes in Working Capital 20.23 5.37 -7.52 9.96 -13.04 -18.40 -53.65 -51.41 -39.14 -40.02 Cash after chg. in Working capital 62.57 45.33 31.19 58.93 46.88 67.80 52.65 52.15 41.67 37.35 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 14.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -4.75 -11.33 -11.48 -18.32 2.92 -67.18 -94.66 -103.89 -95.15 -96.43 Net Fixed Assets 124.42 -5.05 -11.74 18.95 -50.18 -67.39 -93.77 -101.63 -93.38 -94.69 Net Investments 0.00 0.00 28.60 0.00 0.00 0.00 0.00 0.00 -0.37 -3.58 Others -129.17 -6.28 -28.34 -37.27 53.10 0.21 -0.89 -2.26 -1.40 1.84 Cash from Financing Activity -73.00 -35.17 -39.23 -44.13 -46.35 -1.42 40.06 55.15 53.31 59.80 Net Cash Inflow / Outflow -0.74 -1.17 -19.52 -3.51 3.46 -0.79 -1.95 3.41 -0.17 0.72 Opening Cash & Equivalents 2.81 3.98 0.00 7.07 3.62 4.41 6.36 2.95 3.12 2.40 Closing Cash & Equivalent 2.13 2.81 -19.52 3.56 7.07 3.62 4.41 6.36 2.95 3.12

Financial Ratios

Consolidated /

Standalone

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Book Value (Rs.) 269.21 276.25 298.16 319.42 388.42 407.48 408.51 367.54 318.30 265.52 ROA -1.20% -3.66% -3.51% -2.53% 0.14% 0.54% 7.79% 8.68% 9.46% 11.44% ROE -2.44% -7.65% -6.98% -4.83% 0.26% 0.97% 14.26% 16.38% 18.11% 22.65% ROCE 1.15% -0.48% 1.75% 1.50% 5.11% 5.55% 13.40% 14.49% 16.94% 19.29% Fixed Asset Turnover 0.51 0.45 0.54 0.57 0.63 0.77 1.02 1.04 1.12 1.28 Receivable days 34.63 45.68 44.23 46.56 51.33 49.34 40.15 38.45 36.30 34.91 Inventory Days 157.03 167.43 141.69 134.83 126.05 113.85 92.77 87.83 77.16 70.17 Payable days 42.18 37.63 31.43 27.90 25.33 24.89 20.07 14.84 10.66 8.22 Cash Conversion Cycle 149.48 175.48 154.49 153.50 152.04 138.30 112.85 111.44 102.80 96.86 Total Debt/Equity 0.65 0.86 0.82 0.78 0.74 0.68 0.62 0.70 0.71 0.77 Interest Cover 0.52 -0.12 0.34 0.31 1.08 1.05 3.24 3.56 3.02 3.93

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Book Value (Rs.) 262.01 269.42 293.23 314.92 382.47 399.13 403.43 355.10 306.18 254.92 ROA -1.46% -3.85% -4.05% -2.12% 0.20% 0.62% 8.29% 8.87% 9.10% 11.40% ROE -3.05% -8.23% -8.18% -4.13% 0.38% 1.12% 15.38% 17.04% 17.73% 23.07% ROCE 0.90% -0.67% 1.17% 2.00% 5.35% 5.74% 14.06% 14.85% 16.47% 19.24% Fixed Asset Turnover 0.51 0.46 0.54 0.59 0.63 0.76 0.99 1.00 1.06 1.20 Receivable days 36.73 48.37 46.34 49.67 54.45 50.42 37.72 33.88 33.71 32.14 Inventory Days 151.71 159.26 136.61 129.51 124.86 112.15 90.94 87.34 76.56 68.94 Payable days 42.53 37.91 30.30 26.74 26.74 27.25 21.28 15.09 11.03 8.63 Cash Conversion Cycle 145.91 169.72 152.65 152.44 152.57 135.32 107.37 106.14 99.25 92.44 Total Debt/Equity 0.68 0.90 0.85 0.80 0.77 0.70 0.63 0.72 0.74 0.80 Interest Cover 0.40 -0.17 0.23 0.41 1.09 1.06 3.35 3.55 2.85 3.79

Top Investors:

guttikonda vara lakshmi

mona laroia

rajasekhar guttikonda

k.b.shekar

iepf

llp

Annual Reports:

News Update:

Venus Remedies launches full-fledged Consumer Healthcare division
15th Jul 2021, 16:35 PM

The newly launched business division would introduce disruptive products in these segments in India over the next five years
Read More
Venus Remedies unveils covid protection policy
12th Jul 2021, 13:14 PM

The company will pay an amount equivalent to one month of gross salary for the next 12 months to the nominated dependents of permanent employees in case of their untimely demise due to Covid-19
Read More
Venus Remedies wins legal battle against French firm for paracetamol patent
18th Jun 2021, 13:25 PM

The Indian drug firm had initiated the legal battle in order to remove any patent hurdle in manufacturing of intravenous paracetamol solution in the country
Read More

Venus Remedies Ltd.

Pharmaceuticals & Drugs

BSE: 526953 | NSE: VENUSREM

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Venus Remedies Ltd.

Pharmaceuticals & Drugs

BSE: 526953 | NSE: VENUSREM

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: